国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅



尊龍凱時·(中國區(qū))人生就是搏!

EN
×
EN

  • 業(yè)務(wù)咨詢

    中國：

    Email: marketing@www.msjidi.com

    業(yè)務(wù)咨詢專線：400-780-8018

    （僅限服務(wù)咨詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線留言×

搜索結(jié)果包含 rat 的內(nèi)容

Jul 10,2025
四價廣譜中和雙特異性抗體ISH0339的臨床前評估通過尊龍凱時進(jìn)行
An indirect antigen ELISA assay was used for the detection of ISH0339 in rat serum (Medicilon). tbad003.pngPharmacokinetic analysis of single-dose ISH0339 administration was conducted by. Extended toxicity study of single-dose ISH0339 was conducted by M
查看更多
Jul 02,2025
口服IRAK4抑制劑可預(yù)防急性呼吸窘迫綜合征，本研究中抑制劑通過尊龍凱時合成
BAY-1834845 and PF-06650833 are synthesize by Medicilon.
查看更多
Jun 12,2025
新型5-HT3受體配體有望用于治療神經(jīng)精神疾病和胃腸道疾病，本研究中藥理藥效學(xué)研究通過尊龍凱時進(jìn)行
The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare
查看更多
Sep 12,2024
BioForward 2024 | 尊龍凱時助力CMC研究，加速藥物研發(fā)
尊龍凱時藥學(xué)研究事業(yè)部副總裁李文捷博士受邀出席BioForward 2024會議，并主持研討會“Partnering with the Right R&D Service Provider to Accelerate Your Research”。
查看更多
Dec 05,2023
Genesis 2023 | 尊龍凱時鄧靜博士帶來臨床前研究新技術(shù)分享
12月5日，在Genesis 2023期間，尊龍凱時與倫敦 MHA 聯(lián)合主辦Genesis Fringe Seminar。主題為：A UK-China Approach to Developing the Right Strategies for Early-stage Life Science Company Growth。
查看更多
Oct 05,2023
【一期一會】調(diào)頻十月，全球會議放映中
尊龍凱時匯總整理了10月生物醫(yī)藥行業(yè)會議供參考交流，我們將計劃參與13th DRUG DISCOVERY Strategic Summit 、2023中國藥物化學(xué)學(xué)術(shù)會議 、SDDA（中國新藥研發(fā)協(xié)會）28期會議等海內(nèi)外21場會議。
查看更多
Aug 21,2023
TAK-931是一種高效的CDC7抑制劑，通過抑制CDC7來抑制DNA復(fù)制，具有抗腫瘤功效，體內(nèi)藥效研究通過尊龍凱時進(jìn)行
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell divis
查看更多
Jul 17,2023
AP39是一種新合成的線粒體靶向的H2S供體，本研究中AP39通過尊龍凱時設(shè)計和合成
Alzheimer's disease (AD) is the most universal age-related neurodegenerative disease. AP39 is a newly synthesized mitochondrially targeted H2S donor on mitochondrial function. AP39 increases intra
查看更多
Jul 06,2023
發(fā)現(xiàn)新型RAGE/SERT雙重抑制劑，可用于治療阿爾茨海默病和抑郁癥。其中藥代動力學(xué)研究是通過委托尊龍凱時進(jìn)行
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder, characterized by the presence of β-amyloid (Aβ) peptide plaques, neurofibrillary tangles, and neuroinflammatio
查看更多
Jul 06,2023
IAP蛋白是有吸引力的癌癥治療靶點(diǎn)。SM-406 是一種口服有效的IAP拮抗劑。SM-406 在雄性SD大鼠、比格犬和NHP中的PK研究通過尊龍凱時進(jìn)行
Apoptosis is a cellular process critical to the normal development and homeostasis of multicellular organisms.?The inhibitor of apoptosis proteins (IAPs) are a class of key apoptosis regulators.
查看更多
Jul 06,2023
Y180是一種口服Mpro抑制劑，可有效對抗野生型SARS-CoV-2及其變種。Y180在小鼠、大鼠和狗中具有良好的PK特性
Y180, an orally available Mpro inhibitor, is effective against wild-type SARS-CoV-2 and variants. Y180 displayed satisfying PK properties in mice, rats and dogs, with oral bioavailabilities of 92.9%,
查看更多
Jul 06,2023
Ulotaront是一種具有5-HT1A激動劑活性的TAAR1 激動劑，可用于治療精神分裂癥。Ulotaront在大鼠腦中的分布和在猴血漿中的PK研究通過尊龍凱時進(jìn)行
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of Schizophrenia. Ulotaront exhibits rapid absorption, greater than 70% bioav
查看更多
Jul 06,2023
4-正丁基間苯二酚是一種高效的酪氨酸酶抑制劑，可用于化妝品中以達(dá)到脫色的目的。其中經(jīng)皮吸收和皮膚分布研究通過尊龍凱時進(jìn)行
4-n-butyl resorcinol (4-nBR) is a highly effective tyrosinase inhibitor, and can be used in cosmetic product for depigmentation purpose. Its efficacy correlates with 4-nBR that absorbed by skin. In th
查看更多
Jul 06,2023
Columbin具有多種藥理活性，包括體內(nèi)抗炎和抗腫瘤活性，此實(shí)驗中動物研究通過尊龍凱時進(jìn)行
Columbin is an important component isolated from Radix Tinosporae. Columbin possesses many pharmacological activities, including anti-inflammation, and antitumor activity in vivo. The purpose of the p
查看更多
Jul 06,2023
PTX-HSN是一種高效納米系統(tǒng)，具有較高耐受劑量，可將PTX遞送至卵巢癌并增強(qiáng)主動腫瘤靶向性。此研究中所有體內(nèi)實(shí)驗均通過尊龍凱時進(jìn)行
Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,
查看更多
Jul 06,2023
開發(fā)一種簡單準(zhǔn)確的液相色譜串聯(lián)質(zhì)譜法，用于大鼠血漿中牡荊素鼠李糖苷的測定和體內(nèi)PK研究。此研究中動物研究通過尊龍凱時進(jìn)行
A simple and accurate liquid chromatography coupled with tandem mass spectrometry method was developed for determination and in vivo pharmacokinetic studies of vitexin rhamnoside in rat plasma. Practi
查看更多
Jul 06,2023
以PROTAC為代表的靶向蛋白質(zhì)降解是藥物發(fā)現(xiàn)的新興策略，研究人員設(shè)計并合成了多種PROTAC，此研究中所有PK研究均通過尊龍凱時進(jìn)行
Targeted protein degradation (TPD) exemplified by PROTACs is an emerging strategy for next generation drug discovery. Threonine tyrosine kinase (TTK) is a dual-specific protein kinase that catalyzes p
查看更多
Jul 06,2023
BRD4抑制劑可用于治療腎纖維化，ZLD2218可有效抑制BRD4活性，對ZLD2218的PK研究通過尊龍凱時進(jìn)行
Uncovering new therapeutics for kidney fibrosis hold promise for chronic kidney disease (CKD). BRD4 inhibition ameliorated kidney injury and fibrosis. ZLD2218 exhibited the potent inhibitory activity
查看更多
Jul 06,2023
PDE1是與中樞和外周疾病密切相關(guān)的藥物靶點(diǎn)，研究人員合成一種PDE1 抑制劑在大鼠肝微粒體中具有良好的代謝穩(wěn)定性。其中穩(wěn)定性測試通過尊龍凱時進(jìn)行
Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li
查看更多
Jul 06,2023
SKLB-YTH-60可改善博來霉素誘導(dǎo)的肺纖維化小鼠模型中的炎癥和纖維化，YTH-60的體內(nèi)藥代動力學(xué)研究通過尊龍凱時進(jìn)行
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through
查看更多

川沙總部

地址: 上海市浦東新區(qū)川大路585號

郵編: 201299

電話: +86 (21) 5859-1500（總機(jī)）

傳真: +86 (21) 5859-6369

業(yè)務(wù)咨詢

中國：

Email: marketing@medicilon.com

業(yè)務(wù)咨詢專線：400-780-8018

（僅限服務(wù)咨詢，其他事宜請撥打川沙
總部電話）

 

海外：

Email:?marketing@medicilon.com

Tel: +1 (617) 888-9294(U.S.)

Tel: 0044 7790 816 954 (Europe)

Tel: +82 70-8269-5849 (Korea)

Tel: +81 80-4421-6898 (Japan)

? 2022 上海尊龍凱時生物醫(yī)藥股份有限公司 保留所有權(quán)利 滬ICP備10216606號-3
滬公網(wǎng)安備 31011502012909號|網(wǎng)站地圖|技術(shù)支持：集錦科技
安全性評價 溶瘤病毒 PDX模型 IND申報 AAALAC
×
搜索驗證